Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ipilimumab is a fully humanized monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and one of a growing class of immunomodulatory therapies for melanoma. The most common toxicities are immune-related adverse effects (irAEs), which manifest most frequently in the skin as rash and pruritus. We report a case of alopecia areata (AA) attributed to ipilimumab that presented 1.5 years after treatment. Because CTLA-4 dysregulation has been increasingly linked to AA, the incidence of this irAE may increase following US Food and Drug Administration approval of a higher dose of ipilimumab for adjuvant treatment of stage III melanoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alopecia Areata and Risk of Antiphospholipid Syndrome: A Multicenter Retrospective Cohort Study Using Global Electronic Medical Records.
J Cutan Med Surg
September 2025
Evidence-Based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
Impact of Alopecia Areata on Major Life-changing Decisions: Prevalence and Associated Factors.
Acta Derm Venereol
September 2025
Dermatology Unit, Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain; Dermatology Department, School of Medicine, University of Granada, Granada, Spain; Institute of Biosanitary Research IBS, Granada, Spain; Trichology Clinic, Hospital Universitario Virgen de las Nieves, Granad
Alopecia areata is a prevalent autoimmune condition causing non-scarring alopecia, with significant impacts on quality of life. However, the long-term effects on major life-changing decisions remain understudied. A cross-sectional study was performed including patients with alopecia areata who attended the Dermatology Department of the Virgen de las Nieves University Hospital.
View Article and Find Full Text PDFJAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib.
Acta Derm Venereol
September 2025
Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDFCoexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context.
Front Immunol
September 2025
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Background: Bullous Pemphigoid (BP) is caused by a predominantly Th2-mediated attack on the basement membrane by the production of anti-BP180 and anti-BP230 antibodies. Malignant tumors can exacerbate immune disorders through a variety of potential pathways, including pro-inflammatory responses in the tumor microenvironment, cross-immune responses induced by tumor-associated antigens, and the lifting of immunosuppressive states and activation of underlying autoimmune responses after surgery. Alopecia Areata (AA) is an autoimmune disease caused by T-lymphocyte-mediated destruction of the immune privilege of the hair follicle, specifically involving the immune axes of Th1, Th2 and Th17.
View Article and Find Full Text PDF